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Abstract
Molecular docking studies have been carried out for a better understanding of the drug-
receptor interactions. All the synthesized compounds have been subjected to molecular 
docking against targets that have been chosen based on the specific mechanism of action of 
the quinolones used in the antibacterial activity screening. A study of the characteristics and 
molecular properties of the small molecule known as ligand has been realized. In the first 
stage of the study, the 2D and 3D structures have been generated. The most stable conformer 
for each structure was obtained by geometry optimization and energy minimization. A series 
of topological, conformational characteristics and QSAR properties, important to assess the 
flexibility and the ability of the studied conformer to bind to the protein receptor, were deter-
mined and analyzed. These properties were discussed in order to assess the flexibility and 
the binding ability of studied conformers to bind to the receptor protein. The docking stud-
ies have been carried out. The score and hydrogen bonds formed with the amino acids from 
group interaction atoms are used to predict the binding modes, the binding affinities and the 
orientation of the docked quinolones in the active site of the protein receptor.
Keywords: molecular docking, antimicrobial activity, fluoroquinolones, quinolones
1. Introduction
An important parameter in the development of a new drug is the drug’s affinity to the identified 
target (protein/enzyme). Predicting the ligand binding to the target (protein/enzyme) by molec-
ular simulation would allow the synthesis to be restricted to the most promising compounds 
[1–9]. Molecular docking can be accomplished by two interdependent steps [7–9]. The first step 
consists in sampling the ligand conformations in the active site of the protein receptor. The 
second step is to classify these conformations by a scoring function. The sampling algorithms 
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should be able to reproduce experimental binding mode. Various algorithms used for docking 
analysis are molecular dynamics, Monte Carlo methods, genetic algorithms, fragment-based 
methods, point complementary methods and distance geometry methods, systematic searches. 
The scoring function should classify the highest among all the generated conformations. These 
mathematical models are used to predict the strength of binding affinity called noncovalent 
interaction between two molecules after they have been docked. They have also developed scor-
ing function to predict the strength of other types of intermolecular interactions, for example, 
between two proteins or between proteins and DNA or protein and drug. These configura-
tions are evaluated using the scoring functions to distinguish experimental binding modes of 
all other ways explored by the search algorithm. The goal of molecular docking is to predict the 
ligand-receptor complex structure by computation method to identify new active molecules 
that bind to a biological target [10–14]. The main methods used for docking are Lock and Key/
Rigid Docking and Induced Fit/Flexible Docking. In rigid docking, the internal geometry of the 
receptor and ligand is kept fixed and docking is performed. In flexible docking, enumeration 
on the rotations of one of the molecules (usually smaller one) is performed. Every rotation, the 
surface cell occupancy and energy are calculated; later, the most optimum pose is selected.
This chapter presents design and molecular docking studies about 8-chloro-quinolone com-
pounds. The influence of the presence of chlorine atom in the eighth position of the quinolone 
ring (Figure 1, where R
8
 = Cl) on the antimicrobial activity against Staphylococcus aureus has 
been studied. The predicted activity has been correlated with the experimental activity who 
has been determined by agar dilution method [15, 16].
Drugs belonging to the quinolone compound are characterized by a quicker biological activity 
and a larger antibacterial spectrum. They are active on both gram-positive and gram-negative 
bacteria, as well as on recently discovered bacteria with intercellular development (Legionella, 
Mycoplasma, etc.), or even on acid-resistant bacteria (M. tuberculosis and M. leprae). The area of 
use of quinolones has expanded from urinary infections to systemic acute and chronic infections 
(lung and bronchus infections, osteitis, septicemia and endocarditis, chronic infections [chronic 
bronchitis, purulent osteoarthritis, chronic prostatite, cystitis and chronic sinusitis]) [15, 16].
2. Materials and methods
Molecular docking studies have been performed with CLC Drug Discovery Workbench Software 
in order to achieve accurate predictions on optimized conformation for both the quinolone (as 
Figure 1. The structure of the quinolone compounds.
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ligand) and their target receptor protein to form a stable complex. Molecular docking studies have 
been performed on topoisomerase II DNA gyrase with 32 quinolone compounds to understand 
the binding affinity of all quinolones with DNA gyrase. The crystal structure of topoisomerase II 
was downloaded from Protein Data Bank (PDB ID: 2XCT) [17]. The quinolone compounds have 
been synthesized in our laboratory [16], and their structures are shown in Figure 1 and Table 1.
2.1. Ligand preparation
The ligands have been prepared using SPARTAN’14 software package [18]. In this study, the 
DFT/B3LYP/6–31G* level of basis set has been used for the computation of molecular structure, 
vibrational frequencies and energies of optimized structures (Figure 2). In order to perform struc-
ture–activity relationship (SAR) studies, some electronic properties (Table 2) such as highest 
occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy 
values, HOMO and LUMO orbital coefficient distribution, molecular dipole moment, polar 
surface area (PSA), the ovality, polarizability, the octanol water partition coefficient (logP), the 
number of hydrogen-bond donors (HBDs) and ad acceptors (HBAs) and acceptor sites (HBAs) 
and positive and negative ionizable sites are derived from CFD assignments. HBA/HBD and 
±Centers, Hydrophobe Centers including aromatic centers, can be viewed in Figure 2, for the qui-
nolones FPQ 28 and 6ClPQ 28 (compounds that showed good activity against MRSA [19]). The 
polarizability is useful to predict the interactions between nonpolar atoms or groups and other 
electrically charged species, such as ions and polar molecules having a strong dipole moment.
2.1.1. Molecular polar surface area (PSA)
Molecular polar surface area (PSA) [20] is a descriptor that has been shown to correlate well 
with passive molecular transport through membranes and therefore allows the prediction 
of transport properties of the drugs. Log P is estimated according to the method of Ghose, 
Pritchett and Crippen [21]. A number of important graphical quantities resulted from quan-
tum chemical calculations were displayed, manipulated and interrogated. Another indicator 
of electrophilic addition local map is provided by the ionization potential, an overlapping of 
the energy of electron removal (ionization) on the electron density. In addition, the electrostatic 
potential map, an overlay of the electrostatic potential (the attraction or repulsion of a positive 
charge for a molecule) on the electron density, is valuable for describing the overall distri-
bution of molecular charge, as well as to predict the sites of electrophilic addition. Another 
indicator of the electrophilic addition is supplied by the local ionization potential map, an over-
lapping of the energy of electron removal (ionization) on the electron density. In the end, an 
indicator of nucleophilic addition is offered by the |LUMO| map, an overlap of the absolute 
value of the lowest unoccupied molecular orbital (LUMO).
2.1.2. Frontier molecular orbital analysis
The molecular orbital analysis of the Frontier molecular orbitals (FMOs) plays an essential 
role in the chemical stability of a molecule and in the interactions between atoms. They pro-
vide information that can be used to predict the characteristics of molecules such as optical 
properties and biological activities. Between them, the most important are the highest occu-
pied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO). The 
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Compounds R
6
R
7
R
8
NF:1-Ethyl-6-fluoro-7-(piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic 
acid
F Piperazinyl H
FPQ50:1-Ethyl-6-fluoro-7-(piperazin-1-yl)-8-chloro-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid [20]
F Piperazinyl Cl
PF:1-Ethyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
F 4-Methyl-piperazinyl H
FPQ51:1-Ethyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-8-chloro-1,4-dihydro −4-oxo-
quinoline-3-carboxylic acid
F 4-Methyl-piperazinyl Cl
FPQ27:1-Ethyl-6-fluoro-7-(3-methyl-piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid
F 3-Methyl-piperazinyl H
FPQ29.HCl:1-Ethyl-6-fluoro-7-(3-methyl-piperazin-1-yl)-8-chloro-1,4-dihydro-4-
oxo-quinoline-3-carboxylic acid . hydrochloride
F 3-Methyl-piperazinyl Cl
FPQ35:1-Ethyl-6-fluoro-7-(pyrrolidin-1-yl)-1,4-dihydro-4-oxo-quinoline 
−3-carboxylic acid
F Pyrrolidinyl H
FPQ36:1-Ethyl-6-fluoro-7-(pyrrolidin-1-yl)-8-chloro-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid
F Pyrrolidinyl Cl
FPQ32:1-Ethyl-6-fluoro-7-(piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
F Piperidinyl H
FPQ33:1-Ethyl-6-fluoro-7-(piperidin-1-yl)-8-chloro-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid
F Piperidinyl Cl
Q83:1-Ethyl-6-fluoro-7-(4-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
F 4-Methyl-piperidinyl H
Q85:1-Ethyl-6-fluoro-7-(4-methyl-piperidin-1-yl)-8-chloro-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid
F 4-Methyl-piperidinyl Cl
FPQ24:1-Ethyl-6-fluoro-7-(3-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid
F 3-Methyl-piperidinyl H
FPQ30:1-Ethyl-6-fluoro-7-(3-methyl-piperidin-1-yl)-8-chloro-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid
F 3-Methyl-piperidinyl Cl
FPQ25:1-Ethyl-6-fluoro-7-(morpholin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
F Morfolinyl H
FPQ28:1-Ethyl-6-fluoro-7-(morpholin-1-yl)-8-chloro-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid
F Morfolinyl Cl
NClX:1-Ethyl-6-chloro-7-(piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Piperazinyl H
6ClPQ50:1-Ethyl-6,8-dichloro-7-(piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Piperazinyl Cl
PClX:1-Ethyl-6-chloro-7-(4-methyl-piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl 4-Methyl-piperazinyl H
6ClPQ51:1-Ethyl-6,8-dichloro-7-(4-methyl-piperazin-1-yl)-1,4-dihydro −4-oxo-
quinoline-3-carboxylic acid
Cl 4-Methyl-piperazinyl Cl
6ClPQ27:1-Ethyl-6-chloro7-(3-methyl-piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid
Cl 3-Methyl-piperazinyl H
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HOMO represents the ability of a molecule to donate an electron, while the LUMO represents 
the ability to accept an electron [22, 23]. The HOMO and LUMO, calculated at the B3LYP/6-
31G* level, can be seen in Figure 3 for the gas phase, for the quinolones FPQ 28 and 6ClPQ 28 
(compounds that showed good activity against MRSA [19]). The graphic has ‘blue and red’ 
regions. These correspond to positive and negative values of the orbital.
For the HOMO of 7-piperazinyl-8-unsubstituted-quinolones, electron density of NF, PF and 
FPQ27 is localized on piperazine heterocyclic, on aromatic ring and on 4-oxo group. For 
the HOMO of 7-piperazinyl-8-chloro-quinolones, electron density of FPQ 50 and FPQ 51 
is localized on piperazine heterocyclic; for FPQ29 compound, electron density is localized 
on piperazine heterocyclic and C6, C8 and C10 atoms from aromatic ring. For the HOMO 
of 7-piperidinyl-8-unsubstituted-quinolones, electron density of Q 83, FPQ 24 and FPQ 32is 
localized on piperidine heterocyclic, and on C6, C7 and C8 atoms from aromatic ring. For 
the HOMO of 7-piperidinyl-8-chloro-quinolones, electron density of Q 85, FPQ 30 and FPQ 
33is localized on piperidine heterocyclic, on C6, C7 and C8 atoms from aromatic ring and on 
chlorine atom. For the HOMO of 7-morpholinyl-8-unsubstituted-quinolone, FPQ 25 electron 
density is localized on morpholine heterocyclic, on aromatic ring and on 4-oxo group. For 
the HOMO of 7-morpholinyl-8-chloro-quinolone, FPQ 28 electron density is localized on 
Compounds R
6
R
7
R
8
6ClPQ29:1-Ethyl-6,8-dichloro-7-(3-methyl-piperazin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid
Cl 3-Methyl-piperazinyl Cl
6ClPQ35:1-Ethyl-6-chloro-7-(pyrrolidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Pyrrolidinyl H
6ClPQ36:1-Ethyl-6,8-dichloro-7-(pyrrolidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Pyrrolidinyl Cl
6ClPQ32:1-Ethyl-6-chloro-7-(piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Piperidinyl H
6ClPQ33:1-Ethyl-6,8-dichloro-7-(piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Piperidinyl Cl
Q80:1-Ethyl-6-chloro-7-(4-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl 4-Methyl-piperidinyl H
Q87:1-Ethyl-6,8-dichloro-7-(4-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-
3-carboxylic acid
Cl 4-Methyl-piperidinyl Cl
6ClPQ24:1-Ethyl-6-chloro-7-(3-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid
Cl 3-Methyl-piperidinyl H
6ClPQ30:1-Ethyl-6,8-dichloro-7-(3-methyl-piperidin-1-yl)-1,4-dihydro-4-oxo-
quinoline-3-carboxylic acid
Cl 3-Methyl-piperidinyl Cl
6ClPQ25:1-Ethyl-6-chloro-7-(morpholin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Morfolinyl H
6ClPQ28:1-Ethyl-6,8-dichloro-7-(morpholin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid
Cl Morfolinyl Cl
Table 1. The structure of the quinolone compounds.
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Figure 2. Optimized geometry of quinolone compounds.
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morpholine heterocyclic, on aromatic ring, on 4-oxo group and on chlorine atom. For the 
HOMO of 7-pyrrolidinyl-8-unsubstituted-quinolone, FPQ 35 electron density is localized on 
pyrrolidine heterocyclic, on aromatic ring and on 4-oxo group. For the HOMO of 7-pyrro-
lidinyl-8-chloro-quinolone, FPQ 36 electron density is localized on pyrrolidine heterocyclic, 
on aromatic ring, on 4-oxo group and on chlorine atom. For the LUMO of 7-substituted-
8-unsubstituted-quinolones, NF, PF, FPQ27, O 83, FPQ 24, FPQ 32, electron density of FPQ 
25 and FPQ 35 is localized on 4-piridinona ring and on aromatic ring. For the LUMO of 
7-substituted-8-chloro-quinolones, electron density of FPQ 50, FPQ 51, FPQ29, O 85, FPQ 
30, FPQ 33, FPQ 28 and FPQ 36 is localized on 4-piridinona ring, on aromatic ring B and on 
chlorine atom. For the 6-cloroqinolones, the electron density is located in the same manner 
as the corresponding fluoroquinolones.
The frontier orbital gap helps to characterize chemical reactivity of the molecule (Table 2). 
HOMO and LUMOs determine the way in which it interacts with other species. The intro-
duction of the electron-withdrawing substituent (chlorine) at position C 8 in quinolone 
compounds decreases the HOMO-LUMO gap as compared to their corresponding 8-unsub-
stituted quinolone compounds (Figure 4).
2.1.3. Molecular electrostatic potential (MEP)
Molecular electrostatic potential (MEP) has been evaluated using B3LYP method with the 
basis set 6-31G* to investigate the chemical reactivity of a molecule. The MEP is especially 
important for the identification of the reactive sites of nucleophilic or electrophilic attack in 
hydrogen-bonding interactions and for the understanding of the process of biological recog-
nition [21, 22]. An electrostatic potential map for quinolone compounds shows hydrophilic 
regions in red (negative potential) and blue (positive potential) and hydrophobic regions in 
green. In Figure 5 can be viewed the MEP of the quinolones FPQ28 and 6ClPQ28.
The local ionization potential map provides another indicator of electrophilic addition; 
the local ionization map is an overlay of the energy of electron removal (ionization) on the 
Figure 3. HBA/HBD and ±Centers, Hydrophobe centers of 8-chloro-quinolone compounds: (a) FQ28 (b) 6ClPQ28.
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Compounds Molecular properties
Dipole 
moment 
(debye)
E 
HOMO 
(eV)
E 
LUMO 
(eV)
HOMO-
LUMO 
GAP
Polarizability 
(10−30 m3)
PSA(Å2) Ovality Log P HBA 
count
HBD 
count
NF 12.76 −5.76 −1.41 4.35 65.09 56.587 1.45 1.37 5 1
FPQ50 8.71 −6.00 −2.02 3.98 66.33 57.344 1.46 1.92 5 1
PF 12.36 −5.77 −1.43 4.34 66.65 46.369 1.48 1.74 5 1
FPQ51 8.91 −5.79 −1.97 3.82 67.92 46.808 1.49 2.30 5 1
FPQ27 12.86 −5.76 −1.40 4.36 66.57 56.053 1.48 1.68 5 1
FPQ29 9.10 −6.01 −1.96 4.05 67.80 56.717 1.49 2.24 5 1
FPQ35 12.50 −5.77 −1.39 4.38 64.18 44.034 1.43 2.30 4 1
FPQ36 8.83 −6.14 −1.97 4.17 65.44 44.405 1.45 2.86 4 1
FPQ32 9.49 −6.63 −1.82 −4.81 65.58 45.402 1.46 2.72 4 1
FPQ33 8.28 −6.33 −2.05 4.28 66.75 44.781 1.47 3.28 4 1
Q83 9.49 −6.36 −1.82 4.54 67.06 45.389 1.49 3.05 4 1
Q85 8.29 −6.33 −2.05 4.58 68.23 44.785 1.50 3.61 4 1
FPQ24 9.48 −6.34 −1.82 4.52 67.07 45.295 1.48 3.12 4 1
FPQ30 8.23 −6.33 −2.06 4.27 68.24 44.768 1.50 3.68 4 1
FPQ25 10.15 −6.02 −1.58 4.44 64.87 51.758 1.44 1.59 5 1
FPQ28 8.26 −6.24 −1.97 4.97 66.00 51.859 1.45 2.15 5 1
NClX 8.80 −6.08 −1.93 4.15 65.98 57.537 1.47 1.77 5 1
6ClPQ50 7.81 −6.06 −2.11 3.95 67.11 56.756 1.48 2.32 5 1
PClX 11.84 −5.84 −1.59 4.25 67.42 46.688 1.49 2.14 5 1
6ClPQ51 8.69 −5.77 −2.07 3.07 68.72 46.277 1.51 2.70 5 1
6ClPQ27 8.56 −6.13 −1.93 4.20 67.46 57.339 1.59 2.08 5 1
6ClPQ29 8.00 −6.04 −2.10 3.94 68.60 56.469 1.51 2.64 5 1
6ClPQ35 12.16 −5.92 −1.54 4.38 64.92 44.303 1.44 2.70 4 1
6ClPQ36 8.51 −6.05 −2.09 3.96 66.27 43.934 1.47 3.26 4 1
6ClPQ32 9.48 −6.25 −1.89 4.36 66.39 44.937 1.47 3.12 4 1
6ClPQ33 8.26 −6.19 −2.11 4.08 67.57 44.194 1.49 3.68 4 1
Q80 9.47 −6.26 −1.89 5.07 67.86 44.979 1.50 3.45 4 1
Q87 8.26 −6.19 −2.12 4.07 69.04 44.205 1.51 4.01 4 1
6ClPQ24 9.47 −6.24 −1.89 4.35 67.88 44.863 1.50 3.52 4 1
6ClPQ30 8.27 −6.19 −2.12 4.07 69.05 44.304 1.51 4.08 4 1
6ClPQ25 7.85 −6.26 −1.97 4.29 65.69 52.427 1.46 1.99 5 1
6ClPQ28 6.68 −6.20 −2.20 −4.00 66.86 51.596 1.48 2.55 5 1
Table 2. Molecular properties for CPK model computations for quinolone compounds using Spartan’14 V1.1.4 software.
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electron density (Figure 6). |LUMO| map, map that represents a superposition of the abso-
lute value of the lowest unoccupied molecular orbital (the LUMO) on the electron density, 
provides another indicator of the nucleophilic addition (Figure 7).
Figure 4. HOMO, LUMO surfaces of 8-chloro-quinolone compounds: (a) FQ28 (b) 6ClPQ28.
Figure 5. The optimized geometry and electrostatic potential pattern of the surface of (a) FPQ 28 and (b) 6ClPQ 28 (red—
negative, high electron density, blue—positive area, low electron density).
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2.2. Molecular docking
The steps to go through to explore protein-ligand interaction using docking are as follows: 
set up the binding site in a Molecule Project, import the dock ligands to a Molecule Table 
and inspect the docking results. The docking studies have been carried out using CLC Drug 
Discovery Workbench Software. The score and hydrogen bonds formed with the amino acids 
from group interaction atoms are used to predict the binding modes, the binding affinities 
and the orientation of the docked quinolone compounds (Figure 8a–c, e, f, h) in the active site 
of the protein receptor (Table 3). The docking score used in the Drug Discovery Workbench 
is the PLANTS
PLP
 score [24]. The protein-ligand complex has been realized based on the X-ray 
structure of S. aureus DNA GYRASE, who was downloaded from the Protein Data Bank (PDB 
ID: 2XCT) [17].
2.2.1. Docking method validation
It ensures that the ligand orientations and position obtained from the molecular docking stud-
ies are valid and reasonable potential binding modes of ligands; the docking methods and 
parameters used have been validated by redocking (Figure 8d, f).
Figure 7. The optimized geometry and ILUMOI map of (a) FPQ 28 and (b) 6ClPQ 28.
Figure 6. The optimized geometry and local ionization potential map of (a) FPQ 28 and (b) 6ClPQ 28.
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2.2.2. Determining molecular properties
Using the “Calculate Molecular Properties” tool it have been calculated important molecular 
properties such as logP, number of hydrogen bond donors, number of hydrogen bond acceptors 
Figure 8. Molecular docking studies with 2XCT receptor. (a) Docking pose of the co-crystallized ligand CP. (b) Docking 
pose of the co-crystallized ligand CP interacting with residues in the binding site. (c) Docking pose of FPQ 28. (d) Docking 
validation of FPQ 28. (e) Docking pose of the FPQ 28 interacting with residues in the binding site. (f) Docking pose of Q 
83. (g) Docking validation of Q 83. (h) Docking pose of the Q 83 interacting with residues in the binding site.
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Ligand Score/
RMSD (Å)
Group interaction/hydrogen bond Bond 
length (Å)
CP −37.27/
0.79
ASP510, ASP508, ASP512, GLY513, LYS460, GLY459,ARG458, GLU435, 
GLY436, ASP437, SER438
–O sp2 from CO–O sp3 from SER 438
–O sp2 from COOH(CO)–O sp2 from SER 438
–O sp3 from COOH(OH)–O sp2 from ASP 437
3.065
2.816
2.872
ClCP −36.63/
0.10
GLU477, ASP512, ASP437, ARG458,LYS460, ASN475, GLY459, ASN476, 
ILE461
–O sp3 from COOH(OH)–O sp2 from GLU 477
–O sp2 from COOH(CO)–N sp2 from ARG 458
2.933
3.125 
NClX −34.82/
0.06
ASP512, ILE 516, LYS459, ILE461, ARG458, GLU477
–O sp2 from COOH(CO)–Nsp3 from LYS 460 3.036
NF −39.79/
0.11
LYS460, GLY459, ARG458, ILE516, GLU435, ASP512, ASP510, ASP508, 
ARG1033, SER1085, GLY1082, HIS1081, PRO1080
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP 510
2.765
2.802
6ClPQ50 −33.63/
0.07
ASP437, ARG458, GLY459, LYS460, ILE477, LEU462
–N sp3from piperazine–O sp2 from ASP 437
–O sp3 from COOH(OH)–O sp2 from LYS 460
–O sp3 from COOH(OH)–O sp2 from ILE 461
2.840
3.149
3.818
FPQ 50 −38.33/
0.19
GLY582, GLY584, LEU583, ASP508, ASP510 ASP512,LYS460, ILE516, 
GLY459, ARG458, LEU457, ASP437, GLY36, GLU435, SER438, ALA439
–N sp3 from piperazine–N sp3 from LYS 460
–O sp3 from COOH(OH)–O sp2 from ASP 508
–O sp2 from COOH(CO)–N sp2 from ALA 439
3.195
3.036
3.027
PClX −36.00/
0.04
ASP437, ARG458, GLU477,ILE461, LYS460, GLY459,TYR1025
–O sp2 from COOH(CO)–Nsp3 from LYS 460
–O sp2 from CO–Nsp3 from LYS 460
2.809
2.919
PF −39.89/
0.65
ASP512, LYS460, ILE461,GLU477 GLY459, ARG458, ARG1033
–O sp2 from CO–N sp3 from LYS 460
–O sp2 from COOH(CO)–N sp3 from LYS 460
–O sp3 from COOH(OH)–O sp2 from ASP 512
2.732
2.934
2.948
6ClPQ51 −34.98/
0.10
ASP437, ASP512,GLY459, ARG458,GLU477, ASN476,ASN475, ILE461, 
LYS460
–O sp3 from COOH(OH)–O sp2 from GLU 477
–O sp2 from COOH(CO)–N sp2 from ARG 458
2.821
2.929
FPQ 51 −36.50/
0.44
TYR1025, ASP512, HIS515, LYS460, ILE461, LEU519, LEU462, ASN463, 
LYS466, VAL464, ALA467, ARG471
–O sp3 from COOH(OH)–N sp3 from LYS 460
–O sp2 from COOH(CO)–N sp3 from LYS 460
2.888
2.722
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Ligand Score/
RMSD (Å)
Group interaction/hydrogen bond Bond 
length (Å)
6ClPQ27 −35.72/
0.02
SER438, ASP437, GLY436, GLU435, SP508, LEU457, ASP510, ILE516, 
ASP512, LYS460, GLY459, ARG458
–O sp3 from COOH(OH)–O sp2 from ASP 437
–O sp2 from COOH(CO)–O sp3 from SER 438
–O sp2 from CO–O sp3 from SER 438
2.854
2.746
3.073
FPQ 27 −37.06/
1.50
ASP508, GLU435, ASP510, ASP512, ILE516, LYS460,ARG458, ARG1033, 
GLY459, PRO1080, HIS1081, GLY1082, SER1085
–O sp3 from COOH(OH)–O sp2 from ASP510
–O sp2 from COOH(CO)–N sp2 from HIS 1081
3.081
2.726
6ClPQ29 −32.01/
0.16
ASP437, ARG58, GLU477, LYS460, GLY459
–O sp3 from COOH(OH)–O sp2 from ASP 437
–O sp3 from COOH(OH)–O sp2 from ASP 437
2.714
3.389
FPQ 29 −39.67/
0.21
SER185, ARG1033, GLY1082, HIS1081, PRO1080, LYS460, GLY459, ASP512, 
ARG458, ILE516, ASP508, GLU435,ARG458
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP510
2.768
2.804
6ClPQ25 −35.08/
0.32
GLU477, ARG458, LYS460, GLY459, GLU435, ASP512
–O sp3 from COOH(OH)–Nsp3 from LYS 460 2.978
FPQ25 −39.55/
0.04
LYS460, ARG458, GLY459, ILE516, GLU435, ASP512,ASP510, PRO1080, 
HIS1081, GLY1082, SER1084, SER1085
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP 510
2.905
2.632
6ClPQ28 −35.65/
0.22
ILE516, LYS460, GLY513, ASP512, GLY459, ARG458, GLU435, ASP510, 
ASP508,GLY436, ASP437, SER438, ALA439
–O sp3 from COOH(OH)–O sp2 from ASP 437
–O sp2 from COOH(CO)–O sp3 from SER 438
–O sp2 from CO–O sp3 from SER 438
2.968
2.641
2.915
FPQ28 −39.63/
0.17
LYS460, ARG458, GLY459, ILE516, GLU435, ASP508,ASP512, ASP510, 
ARG1033, PRO1080, HIS1081, GLY1082, SER1085
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP 510
2.863
2.671
6ClPQ35 −34.10/
0.02
SER438, ASP437, ALA439, GLY584, GLY436, GLU435, LEU457, ARG458, 
GLY459, LYS460, ASP512, ILE516
–O sp2 from COOH(CO)–O sp3 from SER 438
–O sp2 from COOH(CO)–N sp2 from SER 438
–O sp2 from COOH(CO)–N sp2 from ASP 437
3.174
3.017
2.995
FPQ35 −39.13/
0.18
GLY582, ASP508, GLY584, LEU583, ALA439,SER438, ASP437,GLY436, 
GLU435, ASP510, ASP510, ASP512,LEU457, ARG458, GLY459, LYS460
–O sp3 from COOH(OH)–O sp2 from ASP 508 2.642
Docking Studies on Novel Analogues of 8-Chloro-Quinolones against Staphylococcus aureus
http://dx.doi.org/10.5772/intechopen.72995
89
Ligand Score/
RMSD (Å)
Group interaction/hydrogen bond Bond 
length (Å)
6ClPQ36 −35.59/
0.23
ASP437, ARG458, GLU477,ILE461, LYS460, GLY459,TYR1025
–O sp2 from COOH(CO)–Nsp3 from LYS 460
–O sp2 from CO–Nsp3 from LYS 460
3.070
3.040
FPQ36 −37.23/
0.54
LYS460, GLY459, ILE516, GLU435, ASP508, ASP512, ASP510, ARG1033, 
PRO1080, HIS1081, GLY1082, SER1085
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP 510
2.896
2.614
Q80 −38.37/
0.02
ASP437, ARG458, GLU477, ILE461, LYS460, GLY459
–O sp3 from COOH(OH)–Nsp3 from LYS 460 2.935
Q83 −42.73/
0.07
PRO1080, HIS1081, GLY1082, SER1085, ARG1033, ASP510, ASP508, 
GLU435, ASP12, ILE516, ARG458, LYS460 GLY459
–O sp3 from COOH(OH)–Osp2 from ASP 510
–O sp2 from COOH(CO)–N sp2 from HIS 1081
2.855
2.761
Q87 −34.72/
0.04
ASP512, ASP510, GLY513, ASP508, ILE516, LYS460, GLY459, ARG458, 
LEU457,GLY436, GLU435, ASP437, SER438,ALA439
–O sp3 from COOH(OH)–Osp2 from ASP 437
–O sp2 from COOH(CO)–Osp3 from SER 438
–O sp2 from CO–Osp3 from SER 438
–O sp2 from CO–Nsp2 from SER 438
2.645
2.778
2.792
3.239
Q85 −42.07/
0.08
LYS460, GLY459, ARG458, ILE516, GLU435, ASP512, ASP510, SER1084, 
SER1085, GLY1082, HIS1081, PRO1080
–O sp3 from COOH(OH–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from PRO1080
2.981
2.411
6ClPQ24 −37.07/
0.27
ASN475, ASN476, GLU477,ARG458,SER437, ILE461, LYS460, GLY459
–O sp3 from COOH(OH)–O sp2 from GLU 477
–O sp2 from COOH(CO)–N sp2 from ARG 458
2.962
2.821
FPQ24 −40.64/
0.18
ASP510, ASP512, GLY582, ASP508, LEU583 GLU435, ILE516, LYS460, 
GLY459, ARG458, GLY436, ALA439, SER438, SP437 LEU457
–O sp3 from COOH(OH)–O sp2 from ASP 508 2.644
6ClPQ30 −37.66/
0.0063
ARG458, GLY459, GLU477, LYS460, ILE461, ASN475
–O sp3 from COOH(OH)–N sp3 from LYS 460 3.060
FPQ30 −41.90/
0.32
ARG458, GLY459, LYS460, ILE461,LEU462, ASN463, LEU519, LYS466, 
MET622, HIS515, ASP512, TYR1025
–O sp3 from CO–N sp3 from LYS 460 3.060
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Ligand Score/
RMSD (Å)
Group interaction/hydrogen bond Bond 
length (Å)
6ClPQ32 −33.86/
0.03
SER438, ASP437, ALA439, GLY436,GLU435, LEU457, ASP510, ASP512, 
LYS460, ASP508, ARG458, ILE516, GLY459
–O sp2 from COOH(CO)–O sp3 from SER 438
–O sp2 from CO–O sp3 from SER 438
2.852
2.897
FPQ32 41.85/
0.07
SER1085, ARG458, GLY459, LYS460,ILE516, GLU435, SP508, ASP512, 
ARG1033, LYS462, PRO1080, HIS1081, GLY1082
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP 510
2.775
2.817
6ClPQ33 −35.28/
0.57
LYS460, ILE461, ARG458, GLU477, ASN476
–O sp2 from COOH(CO)–N sp3 from LYS 460 3.073
FPQ33 −42.53/
0.11
ARG458, LYS460, GLY459, ILE516, GLU435, ASP508,ASP512, ASP510, 
ARG1033, PRO1080, HIS1081, GLY1082, SER1085
–O sp2 from COOH(CO)–N sp2 from HIS 1081
–O sp3 from COOH(OH)–O sp2 from ASP 510
2.759
2.830
Table 3. The list of intermolecular interactions between the ligand molecules docked with 2XCT using CLC drug 
discovery workbench software.
Compounds Atoms Weight 
(Daltons)
Flexible 
bonds
Lipinski 
violations
Hydrogen 
donors
Hydrogen 
acceptors
Log P
NF 41 319.33 3 0 2 6 0.68
FPQ50 41 353.78 3 0 2 6 1.31
PF 44 333.36 3 0 1 6 1.15
FPQ51 44 367.80 3 0 1 6 1.77
FPQ27 44 333.36 3 0 2 6 1.11
FPQ29 44 367.80 3 0 2 6 1.74
FPQ35 39 304.32 3 0 1 5 3.90
FPQ36 39 338.76 3 0 1 5 4.53
FPQ32 42 318.34 3 0 1 5 4.26
FPQ33 42 352.79 3 0 1 5 4.89
Q83 45 332.37 3 0 1 5 4.70
Q85 45 366.81 3 1 1 5 5.32
FPQ24 45 332.37 3 0 1 5 4.70
FPQ30 45 366.81 3 1 1 5 5.32
FPQ25 40 320.32 3 0 1 6 3.04
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and molecular weight, parameters  that can be used to evaluate if a molecule has properties that 
would make it a likely orally active drug, according to the Lipinski’s rule of five [25].
• Number of hydrogen bond donors less than 5 (the total number of nitrogen-hydrogen and 
oxygen-hydrogen bonds);
• Number of hydrogen bond acceptors less than 10 (the total number of nitrogen and oxygen 
atoms);
• The molecular weight less than 500 Daltons;
• Log P (octanol–water partition coefficient) less than 5. The calculation of the log P is based 
on the XLOGP3-AA method [26].
The number of violations of the Lipinski rules gives an indication of how drug-likeness for a 
molecule is. In general, orally active drugs have fewer than two violations.
These properties can be useful for identifying potential drug-like molecules, or for removing 
nondrug-like molecules from a compound library before starting a large virtual screening 
experiment (Table 4).
Compounds Atoms Weight 
(Daltons)
Flexible 
bonds
Lipinski 
violations
Hydrogen 
donors
Hydrogen 
acceptors
Log P
FPQ28 40 354.76 3 0 1 6 3.67
NClX 41 335.79 3 0 2 6 0.66
6ClPQ50 41 370.23 3 0 2 6 1.28
PClX 44 349.81 3 0 1 6 1.12
6ClPQ51 44 384.26 3 0 1 6 1.75
6ClPQ27 44 349.81 3 0 2 6 1.09
6ClPQ29 44 384.26 3 0 2 6 1.72
6ClPQ35 39 320.77 3 0 1 5 3.88
6ClPQ36 39 355.22 3 0 1 5 4.51
6ClPQ32 42 334.80 3 0 1 5 4.24
6ClPQ33 42 369.24 3 0 1 5 4.86
Q80 45 348.82 3 0 1 5 4.67
Q87 45 383.27 3 1 1 5 5.30
6ClPQ24 45 348.82 3 0 1 5 4.67
6ClPQ30 45 383.27 3 1 1 5 5.30
6ClPQ25 40 336.77 3 0 1 6 3.02
6ClPQ28 40 371.22 3 0 1 6 3.64
Table 4. Ligands with properties.
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3. Results and discussions
Molecular docking study has been performed relating to some quinolone compounds known 
in medical therapeutics: ciprofloxacin, norfloxacin and pefloxacin. For a correct interpretation 
of the data has been used in the study the corresponding compound of ciprofloxacin, ClCp. 
Figure 9. Docking pose of quinolone compounds in the binding site. (a) The quinolones with the similar binding mode 
of the co-crystallized ligand Cp. (b) The quinolones with the similar binding mode of the ClCp. (c) The quinolones with 
the similar binding mode of the ligand NF. (d) The quinolones with the similar binding mode of the ligand PF. (e) The 
quinolones with the similar binding mode of the ligand FPQ 35.
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ClCp is the compound having a chlorine atom in 6-position of quinolone ring in place of 
fluorine atom.
The result of molecular docking study for quinolone FPQ 28, compound with a good activity 
‘in vitro’ against Staphylococcus aureus ATCC 6538 (MIC = 0.32 μg/ml) and with a good activity 
against MRSA [19], reveals docking score −39.63 (RMSD 0.17) and shows the occurrence of two 
hydrogen bonds with HIS 1081 (2.863 Å) and ASP 510 (2.671 Å) (Figure 8c). The orientation of 
the FPQ 28 is the same of NF (norfloxacin). Same orientation shows also the compounds: FPQ 
32, FPQ 33, Q 83, Q 85, FPQ 27, FPQ 29, FPQ24 and FPQ 25 (Figure 9c). Docking score of NF 
compound is −39.79 (RMSD 0.11). NF shows the occurrence of two hydrogen bonds with HIS 
1081 (2.863 Å) and ASP 510 (2.671 Å). The better score docking has been obtained from quino-
lone Q83: −42.73 (RMSD 0.07). Q83 shows the occurrence of two hydrogen bonds with HIS 1081 
(2.761 Å) and ASP 510 (2.855 Å), and its orientation is the same of NF. Compound Q83 shows 
also a good activity ‘in vitro’ against Staphylococcus aureus ATCC 6538 (MIC <0.125 μg/ml).
Results of the docking showed that quinolones have adopted various orientations. The same 
orientation with the co-crystallized ligand Cp (ciprofloxacin) shows the compound 6 ClPQ 
27, 6ClPQ 28, 6ClPQ35 and Q 87. Co-crystallized Cp shows the occurrence of three hydrogen 
bonds with SER 438 (3.065 Å), SER 438 (2.816 Å) and ASP 437 (2.872 Å) (Figure 9a). The quino-
lones with the similar binding mode of the ClCp are 6ClPQ 51 and 6ClPQ 24 (Figure 9b). The 
quinolones with the similar binding mode of the ligand PF (pefloxacin) are 6ClPQ50, NClX, 
6ClPQ 25, Q 80, FPQ 30, 6 ClPQ 33, PClX, FPQ 51, 6 ClPQ 36 and 6ClPQ 30.Docking score 
of PF is −39.89 (RMSD 0.65).PF shows the occurrence of three hydrogen bonds with LYS 460 
(2.732 Å), LYS 460 (2.934 Å) and ASP 512 (2.948 Å) (Figure 9d). Same orientation shows the 
compounds FPQ 35, FPQ 24 and FPQ 50 (Figure 9e).
3.1. Drug-likeness of the quinolone compounds
According to the data presented in Table 4, four quinolones (Q 85, Q 87, FPQ 30 and 6ClPQ30) 
failed to respect one parameter (Log P > 5) of the Lipinski rules (Lipinski violation is 1). It was 
observed that 30 compounds of the study have zero violation of all the parameters involved 
in Lipinski’s rule of five.
4. Conclusions
In silico molecular docking, simulation was performed to position all quinolone compounds 
into the preferred binding site of the protein receptor S. aureus DNA GYRASE, to predict the 
binding modes, the binding affinities and the orientation. The docking studies revealed that 
the all compounds showed good docking score. The docking score is a measure of the antimi-
crobial activity of the studied compounds. A correlation of the predicted data was observed 
which is obtained by molecular docking study (score docking) with the experimental data 
obtained from the evaluation of the antimicrobial activity against Staphylococcus aureus ATCC 
6538 [16] of the quinolone compounds (Figure 10a, b, and 11a, b).
The studies presented in this chapter show the importance of the design and the molecular 
docking in the discovery of new compounds with biological activity. The prediction of the 
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Figure 10. (a) MIC histogram of 6-fluoro-quinolone compounds. Minimum inhibitory concentration (MIC) of quinolone 
compounds against St. aur. ATCC 6538 (8-H-fluoroquinolones-blue, 8-Cl-fluoroquinolones-red). (b) Score docking of 
6-fluoro-quinolone compounds (8-H-fluoroquinolones-blue, 8-Cl-fluoroquinolones-red).
Figure 11. (a) MIC histogram of 6-chloro-quinolone compounds. Minimum inhibitory concentration (MIC) of quinolone 
compounds against St. aur. ATCC 6538 (8-H-chloroquinolones-blue, 8-Cl-chloroquinolones-red). (b). Score docking of 
6-chloro-quinolone compounds (8-H-chloroquinolones-blue, 8-Cl-chloroquinolones-red).
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binding affinity of a new compound (ligand) to an identified target (protein/enzyme) is a 
significant parameter in the development of a new drug. The prediction of the binding mode 
of a ligand (a new compound) to the target (protein/enzyme) by molecular simulation would 
allow restricting the synthesis to the most promising compounds.
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